|
Artelo Biosciences ، Inc. (ARTL) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Artelo Biosciences, Inc. (ARTL) Bundle
تقييم التوقعات المالية لـ Artelo Biosciences ، Inc. (ARTL) بدقة الخبراء! توفر لك حاسبة DCF (ARTL) هذه البيانات المالية المليئة مسبقًا وحرية تعديل نمو الإيرادات و WACC والهوامش والافتراضات الأساسية الأخرى التي تتماشى مع توقعاتك.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2018 |
AY2 2019 |
AY3 2020 |
AY4 2021 |
AY5 2022 |
FY1 2023 |
FY2 2024 |
FY3 2025 |
FY4 2026 |
FY5 2027 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -2.3 | -4.2 | -4.7 | -7.4 | -10.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -2.3 | -4.2 | -4.7 | -7.4 | -10.3 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | .3 | 4.4 | 2.1 | 10.1 | 17.5 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .5 | .3 | .5 | .5 | .9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | -1.5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 |
| EBITAT | -2.3 | -4.2 | -4.7 | -7.4 | -10.1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1.8 | -5.9 | -4.6 | -7.4 | -9.7 | -.9 | .0 | .0 | .0 | .0 |
| WACC, % | 9.89 | 9.89 | 9.89 | 9.89 | 9.89 | 9.89 | 9.89 | 9.89 | 9.89 | 9.89 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -7 | |||||||||
| Equity Value | 6 | |||||||||
| Diluted Shares Outstanding, MM | 3 | |||||||||
| Equity Value Per Share | 2.12 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to create various scenarios.
- Real-World Data: Artelo Biosciences, Inc. (ARTL) financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A sleek Excel model that adapts to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing projections, validating strategies, and enhancing efficiency.
Key Features
- 🔍 Real-Life ARTL Financials: Pre-filled historical and projected data for Artelo Biosciences, Inc. (ARTL).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Artelo’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Artelo’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file for Artelo Biosciences, Inc. (ARTL).
- Step 2: Review Artelo’s pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for informed investment choices.
Why Choose This Calculator?
- User-Friendly Interface: Perfect for both novices and seasoned professionals.
- Customizable Inputs: Adjust variables to suit your financial model and analysis.
- Real-Time Valuation: Witness immediate updates to Artelo Biosciences' valuation as you change inputs.
- Preloaded Data: Comes equipped with Artelo's latest financial information for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use Artelo Biosciences, Inc. (ARTL)?
- Investors: Gain insights into innovative biotech solutions and make informed investment choices.
- Healthcare Analysts: Utilize comprehensive data to analyze market trends and company performance.
- Consultants: Easily tailor presentations or reports on biotech advancements for clients.
- Biotech Enthusiasts: Expand your knowledge of cutting-edge therapies and their potential impact.
- Educators and Students: Leverage real-world case studies in biotechnology for academic purposes.
What the Template Contains
- Historical Data: Includes Artelo Biosciences, Inc.'s (ARTL) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Artelo Biosciences, Inc.'s (ARTL) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital specific to Artelo Biosciences, Inc. (ARTL).
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions for Artelo Biosciences, Inc. (ARTL).
- Quarterly and Annual Statements: A complete breakdown of Artelo Biosciences, Inc.'s (ARTL) financials.
- Interactive Dashboard: Visualize valuation results and projections for Artelo Biosciences, Inc. (ARTL) dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.